Cibc World Markets Corp Acquires New Stake in Haemonetics Co. (NYSE:HAE)

Cibc World Markets Corp acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,696 shares of the medical instruments supplier's stock, valued at approximately $367,000.

Other hedge funds have also made changes to their positions in the company. Parkside Financial Bank & Trust boosted its holdings in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares in the last quarter. KBC Group NV boosted its holdings in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 712 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in shares of Haemonetics in the 3rd quarter valued at $204,000. Finally, HighTower Advisors LLC raised its stake in Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Price Performance

HAE traded down $0.86 on Tuesday, hitting $63.60. 213,499 shares of the company were exchanged, compared to its average volume of 649,929. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market capitalization of $3.19 billion, a P/E ratio of 25.03, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The business's fifty day moving average is $66.99 and its 200 day moving average is $74.96.

Remove Ads

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Finally, JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.